(Q34013882)

English

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

prostate cancer

1 reference

based on heuristic

inferred from title

5

object named as

Alan W Partin

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Connie Collins

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Michael A Carducci

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Mario A Eisenberger

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

John T Isaacs

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Roberto Pili

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Victoria J Sinibaldi

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Janet S Walczak

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Samuel R Denmeade

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

publication date

5 June 2007

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Cancer Biology and Therapy

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1360-1367

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Combinatorial androgen receptor targeted therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

28 July 2018

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

28 July 2018

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

28 July 2018

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

28 July 2018

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

28 July 2018

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

28 July 2018

From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

28 July 2018

Implication of cell kinetic changes during the progression of human prostatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

28 July 2018

Intracellular signaling pathways activated by neurotrophic factors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

28 July 2018

Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

28 July 2018

Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: partial purification and characterization of rat prostatic growth factor in the Dunning tumor.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

28 July 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

28 July 2018

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

29 October 2018

A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

29 October 2018

Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation--rescue of transcriptionally compromised mutants

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

29 October 2018

Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

29 October 2018

Rational basis for Trk inhibition therapy for prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

29 October 2018

Regional loss of imprinting of the insulin-like growth factor II gene occurs in human prostate tissues.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4124640

29 October 2018

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/17786033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/17786033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/17786033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical pharmacology of UCN-01: initial observations and comparison to preclinical models

1 reference

https://pubmed.ncbi.nlm.nih.gov/17786033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/17786033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17786033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/17786033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan

1 reference

https://pubmed.ncbi.nlm.nih.gov/17786033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587)

1 reference

https://pubmed.ncbi.nlm.nih.gov/17786033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Production of IGF-II-related peptide by an anaplastic cell line (AT-3) established from the Dunning prostatic carcinoma of rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/17786033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Response of prostate cancer to anti-Her-2/neu antibody in androgen-dependent and -independent human xenograft models

1 reference

https://pubmed.ncbi.nlm.nih.gov/17786033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555)

1 reference

https://pubmed.ncbi.nlm.nih.gov/17786033

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.4161/CBT.6.9.4541

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34013882&oldid=1966844608"